or Try an Advanced Search...

    Bispecific Monoclonal Antibody Stocks List

    Symbol Grade Name % Change
    ZYME C Zymeworks Inc. -4.54
    OABI D OmniAb, Inc. 0.51
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Antibody Glycoproteins Immune System Immunology Medicine Monoclonal Antibodies Antibodies Biological Systems Biopharmaceutical Biotechnology Cancer Cancer Immunotherapy Her2 Immunization Mining Polyclonal Antibodies Protein Engineering Toxins

    Related ETFs - A few ETFs which own one or more of the above listed Bispecific Monoclonal Antibody stocks.

    Symbol Grade Name Weight
    IDNA D iShares Genomics Immunology and Healthcare ETF 0.47
    IWC B iShares Microcap ETF 0.3
    IBB D iShares Nasdaq Biotechnology Index Fund 0.14
    SMMV B iShares MSCI USA Small-Cap Min Vol Factor ETF 0.13
    IWN B iShares Russell 2000 Value ETF 0.08
    View all Bispecific Monoclonal Antibody ETFs...
    Compare ETFs
    Compare IBB to IWN Compare IBB to SMMV Compare IDNA to IBB

        Bispecific Monoclonal Antibody Stocks Recent News

        Date Stock Title
        Nov 21 ZYME Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
        Nov 21 ZYME FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
        Related Industries: Biotechnology
        Related Stock Lists: Antibody Glycoproteins Immune System Immunology Medicine Monoclonal Antibodies Antibodies Biological Systems Biopharmaceutical Biotechnology Cancer Cancer Immunotherapy Her2 Immunization Mining Polyclonal Antibodies Protein Engineering Toxins
        Bispecific Monoclonal Antibody

        A bispecific monoclonal antibody (bsMAb) is a type of antibody that is engineered to bind to two different antigens simultaneously. This type of antibody has the potential to be used in a variety of therapeutic applications, such as cancer immunotherapy, autoimmune diseases, and infectious diseases. BsMAbs can be used to target two different antigens on the same cell, or two different antigens on different cells. This allows for more precise targeting of the desired antigen, and can potentially reduce the side effects associated with traditional monoclonal antibody therapies.

        Browse All Tags